Researchers evaluated whether breast cancer patients with hypothyroidism at diagnosis or who develop it later have an increased risk of recurrence or death.
The long-term results of the phase III HannaH trial confirmed the similarity between the subcutaneous and intravenous formulation of trastuzumab in patients with HER2+ breast cancer.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: MultiMedia Healthcare
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA